LMNL

Liminal BioSciences Inc. [LMNL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LMNL Stock Summary

In the News

12:36 29 Mar 2024 LMNL

Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder

If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.

07:48 29 Mar 2024 LMNL

Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management

Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.

10:56 29 Mar 2024 LMNL

Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?

Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.

08:08 29 Mar 2024 LMNL

Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price

Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.

04:08 29 Mar 2024 LMNL

Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.

04:38 29 Mar 2024 LMNL

Liminal BioSciences to Present at BIO CEO & Investor Conference

LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.

10:17 29 Mar 2024 LMNL

Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript

Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.

03:22 29 Mar 2024 LMNL

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.

08:30 29 Mar 2024 LMNL

Liminal Biosciences to Present at Upcoming Investor Conferences

LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).

06:52 29 Mar 2024 LMNL

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia.  The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.

LMNL Financial details

Company Rating
Sell
Market Cap
27.62M
Income
354K
Revenue
492K
Book val./share
6.92
Cash/share
6.22
Dividend
-
Dividend %
-
Employees
251
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
99.67
Forward P/E
-
PEG
-9.93
P/S
75.08
P/B
1.64
P/C
-
P/FCF
-1.02
Quick Ratio
2.18
Current Ratio
2.78
Debt / Equity
0.06
LT Debt / Equity
0.02
-
-
EPS (TTM)
0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-37.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-66.94%
Revenue last 5Y
-61.49%
Revenue Q/Q
-17.65%
EPS Q/Q
19.51%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
1%
ROE
1%
ROC
-1.5%
Gross Margin
100%
Oper. Margin
-6900%
Profit Margin
72%
Payout
-
Shs Outstand
3.25M
Shs Float
1.26M
-
-
-
-
Target Price
-
52W Range
3.1-8.5
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
23.73K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
29.3405
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

LMNL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
572.153.051.360.210.13
Net income per share
-2.36K-145.82-49.97-14.94-9.32
Operating cash flow per share
-995.82-61.88-31.06-33.02-10.25
Free cash flow per share
-1.06K-64.65-31.9-33.18-10.26
Cash per share
89.2438.1618.4435.9711.97
Book value per share
-683.6263.629.4514.1411.66
Tangible book value per share
-1K50.48-0.210.0710.62
Share holders equity per share
-683.6263.629.4514.1411.66
Interest debt per share
1.88K38.0633.8422.250.83
Market cap
219.94M175.8M130.88M41.9M13.66M
Enterprise value
346.05M161.58M159.79M-5.81M-22M
P/E ratio
-1.13-0.75-1.07-0.93-0.47
Price to sales ratio
4.6435.8539.4665.1634.06
POCF ratio
-2.67-1.77-1.72-0.42-0.43
PFCF ratio
-2.51-1.69-1.68-0.42-0.43
P/B Ratio
-3.891.725.670.980.38
PTB ratio
-3.891.725.670.980.38
EV to sales
7.332.9548.17-9.04-54.86
Enterprise value over EBITDA
-3.2-0.8-1.860.130.69
EV to operating cash flow
-4.2-1.63-2.10.060.69
EV to free cash flow
-3.95-1.56-2.050.060.69
Earnings yield
-0.89-1.33-0.93-1.08-2.12
Free cash flow yield
-0.4-0.59-0.6-2.39-2.33
Debt to equity
-2.360.463.21.430.04
Debt to assets
1.30.290.630.480.03
Net debt to EBITDA
-1.170.07-0.341.061.12
Current ratio
1.143.033.076.24.09
Interest coverage
-5.08-14.99-10.81-7.83-30.59
Income quality
0.350.480.64-8.16-51.16
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
1.9315.3217.1328.5338.15
Intangibles to total assets
0.190.080.130.030.06
Capex to operating cash flow
0.060.040.0300
Capex to revenue
-0.11-0.91-0.62-0.72-0.05
Capex to depreciation
-0.94-0.45-0.24-0.11-0.02
Stock based compensation to revenue
0.144.411.876.584.65
Graham number
6.02K456.89103.0968.9449.45
ROIC
-1.24-1.12-0.72-0.39-0.83
Return on tangible assets
-2.35-1.55-1.19-0.37-0.61
Graham Net
-1.66K3.03-20.495.687.66
Working capital
5.11M63.59M49.24M96.14M31.22M
Tangible asset value
-82.95M81.09M-480K30.37M32.97M
Net current asset value
-125.2M24.69M-29.75M22.46M27.07M
Invested capital
-2.360.463.21.430.04
Average receivables
15.46M16.64M8.6M2.49M1.12M
Average payables
20.22M15.8M9.82M7.46M4.58M
Average inventory
24.02M9.78M8.45M4.69M0
Days sales outstanding
153.88989.91429.48606.251.07K
Days payables outstanding
202.631.39K1.64K00
Days of inventory on hand
115.539951.68K00
Receivables turnover
2.370.370.850.60.34
Payables turnover
1.80.260.2200
Inventory turnover
3.160.370.2200
ROE
3.45-2.29-5.29-1.06-0.8
Capex per share
-61.93-2.77-0.84-0.15-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.0500.080.040.04
Net income per share
-1.017.06-1.54-2.46-2.94
Operating cash flow per share
-2.18-3.77-2.03-3.33-2.51
Free cash flow per share
-2.19-3.77-2.02-3.33-2.51
Cash per share
17.9813.1311.978.686.22
Book value per share
8.7813.0211.679.366.92
Tangible book value per share
5.6913.0210.629.366.92
Share holders equity per share
8.7813.0211.679.366.92
Interest debt per share
7.730.810.420.510.39
Market cap
20.51M17.83M13.65M11.8M25.93M
Enterprise value
-12.17M-21.36M-22M-13.79M7.82M
P/E ratio
-1.640.2-0.72-0.39-0.71
Price to sales ratio
130.675.94K56.6586.73231.48
POCF ratio
-3.03-1.52-2.17-1.14-3.33
PFCF ratio
-3.02-1.52-2.17-1.14-3.33
P/B Ratio
0.750.440.380.411.21
PTB ratio
0.750.440.380.411.21
EV to sales
-77.54-7.12K-91.3-101.469.83
Enterprise value over EBITDA
1.492.123.11.94-0.88
EV to operating cash flow
1.81.833.491.33-1.01
EV to free cash flow
1.791.833.51.33-1.01
Earnings yield
-0.151.23-0.35-0.65-0.35
Free cash flow yield
-0.33-0.66-0.46-0.88-0.3
Debt to equity
0.850.040.040.050.06
Debt to assets
0.330.030.030.030.04
Net debt to EBITDA
4.013.895.033.62.04
Current ratio
2.354.854.093.752.78
Interest coverage
-9.71-10.8238.4-34.10
Income quality
1.09-0.531.481.390.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
29.61.46K37.4826.1742.64
Research and developement to revenue
25.111.17K14.3730.6538.74
Intangibles to total assets
0.050.060.060.080.14
Capex to operating cash flow
00000
Capex to revenue
-0.05-10.0800
Capex to depreciation
-0.03-0.010.0700
Stock based compensation to revenue
3.42137.671.222.112.17
Graham number
14.1145.4720.0922.7821.41
ROIC
-0.061.52-0.13-0.23-0.38
Return on tangible assets
-0.050.43-0.1-0.21-0.33
Graham Net
1.199.147.665.673.09
Working capital
35M35.18M31.22M25.05M16.4M
Tangible asset value
14.27M37.1M32.97M25.89M17.06M
Net current asset value
7.77M30.82M27.07M24.06M15.32M
Invested capital
0.850.040.040.050.06
Average receivables
1.14M1.49M1.34M1.1M909K
Average payables
4.05M01.7M1.7M0
Average inventory
00000
Days sales outstanding
848.4144.94K439.54681.62633.21
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.1100.20.130.14
Payables turnover
00000
Inventory turnover
00000
ROE
-0.110.54-0.13-0.26-0.43
Capex per share
000.0100

LMNL Frequently Asked Questions

What is Liminal BioSciences Inc. stock symbol ?

Liminal BioSciences Inc. is a CA stock , located in Laval of Qc and trading under the symbol LMNL

What is Liminal BioSciences Inc. stock quote today ?

Liminal BioSciences Inc. stock price is $- today.

Is Liminal BioSciences Inc. stock public?

Yes, Liminal BioSciences Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap